1. BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). (June 2017) Authors: Cramer, P.; von Tresckow, J.; Bahlo, J.; Robrecht, S.; Al‐Sawaf, O.; Langerbeins, P.; Engelke, A.; Fink, A.M.; Fischer, K.; Seiler, T.; von Weikersthal, L.Fischer; Hebart, H.; Kreuzer, K.A.; Ritgen, M.; Kneba, M.; Wendtner, C.M.; Stilgenbauer, S.; Eichhorst, B.; Hallek, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. (12th June 2019) Authors: Fischer, K.; Porro Lurà, M.; Al‐Sawaf, O.; Bahlo, J.; Fink, A.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; Liberati, A.M.; Pinilla‐Ibarz, J.; Opat, S.; Sivcheva, L.; Le Dû, K.; Fogliatto, L.M.; Utoft Niemann, C.; Weinkove, R.; Robinson, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient. (12th June 2019) Authors: Tausch, E.; Bahlo, J.; Robrecht, S.; Schneider, C.; Bloehdorn, J.; Schrell, S.; Galler, C.; Al‐Sawaf, O.; Fink, A.; Eichhorst, B.; Kreuzer, K.; Tandon, M.; Humphrey, K.; Jiang, Y.; Schary, W.; Porro Lurà, M.; Döhner, H.; Fischer, K.; Hallek, M.; Stilgenbauer, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL. (12th June 2019) Authors: Al‐Sawaf, O.; Lilienweiss, E.; Bahlo, J.; Robrecht, S.; Fink, A.; Patz, M.; Tandon, M.; Humphrey, K.; Jiang, Y.; Schary, W.; Porro Lurà, M.; Ritgen, M.; Tausch, E.; Stilgenbauer, S.; Eichhorst, B.; Fischer, K.; Hallek, M.; Kreuzer, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS. (23rd June 2022) Authors: Cramer, P.; Fürstenau, M.; Giza, A.; Robrecht, S.; Tausch, E.; Schneider, C.; Wendtner, C.-M.; Hoechstetter, M.; Schetelig, J.; Böttcher, S.; Dreger, P.; Fink, A.-M.; Langerbeins, P.; Al-Sawaf, O.; Fischer, K.; Stilgenbauer, S.; Eichhorst, B.; Hallek, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 539 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P652: MEASURING MINIMAL RESIDUAL DISEASE BEYOND 10-4 THROUGH IGHV LEADER-BASED NEXT GENERATION SEQUENCING IMPROVES PROGNOSTIC STRATIFICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA. (23rd June 2022) Authors: Hengeveld, P.; van der Klift, M.; Kolijn, P. M.; Davi, F.; Kavelaars, F.; de Jonge, E.; Robrecht, S.; Assmann, J.; van der Straten, L.; Ritgen, M.; Westerweel, P.; Fischer, K.; Goede, V.; Hallek, M.; Levin, M.-D.; Langerak, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 550 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB. (23rd June 2022) Authors: Al-Sawaf, O.; Jin, H. Y.; Zhang, C.; Choi, Y.; Balasubramanian, S.; Robrecht, S.; Kotak, A.; Chang, N.; Fink, A.-M.; Tausch, E.; Schneider, C.; Ritgen, M.; Kreuzer, K.-A.; Chyla, B.; Paulson, J.; Eichhorst, B.; Stilgenbauer, S.; Jiang, Y.; Hallek, M.; Fischer, K. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY. (23rd June 2022) Authors: Al-Sawaf, O.; Zhang, C.; Robrecht, S.; Kotak, A.; Chang, N.; Fink, A.-M.; Tausch, E.; Schneider, C.; Ritgen, M.; Kreuzer, K.-A.; Chyla, B.; Eichhorst, B.; Jiang, Y.; Stilgenbauer, S.; Hallek, M.; Fischer, K. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY. (17th June 2021) Authors: Al‐Sawaf, O.; Zhang, C.; Robrecht, S.; Tandon, M.; Panchal, A.; Fink, A.‐M.; Tausch, E.; Ritgen, M.; Kreuzer, K.‐A.; Kim, S.; Wendtner, C.; Eichhorst, B.; Stilgenbauer, S.; Jiang, Y.; Hallek, M.; Fischer, K. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗